Adams Harkness Cuts MedImmune to 'Market Perform'

Analyst Felicia Reed thinks the sales of the drugmaker's just-approved flu vaccine will be lackluster

Adams Harkness downgraded MedImmune (MEDI ) to market perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.